Alnylam charged Tekmira with wrongly using trade secrets to bolster its own drug delivery technology-development efforts and to file a patent application on Alnylam's phase I liver cancer drug.
The high court has ruled in favor of Roche, saying that just because university-based research may been funded by federal dollars it does not override more than 200 years of patent law and take away the rights to a patent from its inventor.
Celera and other defendants have entered into a memorandum of understanding in putative class action lawsuits stemming from the company's proposed acquisition by Quest Diagnostics.
Genetic Technologies granted a non-exclusive license to Orchid Cellmark for a number of patents covering non-coding analysis, gene mapping, and internal standards.
Alnylam charged that Tekmira has itself violated the companies' agreements by filing the suit, which it said ignores “confidential and non-public alternative dispute resolution procedures required under the … agreements."
Brenda Bass “conceived the inventions of all the issued claims of Tuschl-II and at least some pending claims of Tuschl-I well before any date asserted by the currently named inventors,” the University of Utah alleges.
